High levels of soluble CD73 unveil resistance to BRAF inhibitors in melanoma cells

Melanoma cells express high levels of CD73 that produce extracellular immunosuppressive adenosine. Changes in the CD73 expression occur in response to tumor environmental factors, contributing to tumor phenotype plasticity and therapeutic resistance. Previously, we have observed that CD73 expression...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Biomedicine & pharmacotherapy 2024-08, Vol.177, p.117033, Article 117033
Hauptverfasser:	Giraulo, Caterina, Orlando, Lavinia, Morretta, Elva, Voli, Antonia, Plaitano, Paola, Cicala, Carla, Potaptschuk, Eugen, Müller, Christa E., Tosco, Alessandra, Monti, Maria Chiara, Morello, Silvana
Format:	Artikel
Sprache:	eng
Schlagworte:	5'-Nucleotidase - genetics 5'-Nucleotidase - metabolism BRAF inhibitor CD73 Cell Line, Tumor Drug Resistance, Neoplasm - drug effects GPI-Linked Proteins - genetics GPI-Linked Proteins - metabolism Humans Imidazoles - pharmacology Matrix Metalloproteinase 9 - metabolism Melanoma - drug therapy Melanoma - genetics Melanoma - metabolism Melanoma - pathology melanoma cells MMP9 Oximes - pharmacology Protein Kinase Inhibitors - pharmacology Proto-Oncogene Mas Proto-Oncogene Proteins B-raf - antagonists & inhibitors Proto-Oncogene Proteins B-raf - genetics Proto-Oncogene Proteins B-raf - metabolism Vemurafenib - pharmacology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!